MDS 2023 | Cleveland Clinic Journal of Medicine
Highlights from International Congress of Parkinson’s Disease and Movement Disorders®, held from August 27 – 31, 2023.
High response rate as early as 4 weeks after incobotulinumtoxinA injection for upper limb spasticity
Presenter: Franco Molteni, MD, Valduce Villa Beretta Hospital, Costa Masnaga, Italy
Improvement in spasticity-associated dressing- and hygiene-related disability in adults following treatment with incobotulinumtoxinA: a pooled analysis.
Fast onset of action with valbenazine for treatment of chorea associated with Huntington disease
Presenter: Raja Mehanna, MD, University of Texas Health Science Center, Houston, TX
Indirect treatment comparison of valbenazine with deutetrabenazine for improvement in total maximal chorea score in Huntington disease.
Menopause linked to worsening of PD symptoms
Presenter: Willanka Kapelle, MD, Radboud University Medical Centre, Nijmegen, The Netherlands
Women and PD: experienced changes in Parkinson symptoms after menopause.
GLP1-R agonist improves Parkinson disease symptoms in early disease
Presenter: Wassilios G. Meissner, MD, PhD, University Hospital Bordeaux, France
Multicenter, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept study of lixisenatide in patients with early Parkinson’s disease (PD): the LIXIPARK trial.
Tardive dyskinesia has significant burden on patient quality of life, worsening the development and treatment of underlying psychiatric conditions
Presenter: Rinat Ribalov, BSc Pharm, Teva Pharmaceuticals Industries Ltd, Tel Aviv, Israel
Burden and management of tardive dyskinesia (TD): a cross-sectional international survey study to assess the perceptions and experiences of patients with TD.
Chorea improvement in Huntington disease starts as early as week 2 with valbenazin
Presenter: Erin Furr Stimming, MD, University of Texas Health Science Center, Houston, TX
Chorea improvements over time with once-daily valbenazine treatment in adults with Huntington disease.
Improvements in tardive dyskinesia with treatment are consistent across two outcomes scales
Presenter: Maria Mercedes Perez-Rodriguez, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY.
Treatment-related improvements in tardive dyskinesia symptoms are similar for both clinician-related and patient-reported scales.
Machine learning tool can distinguish tics from spontaneous movements
Presenter: Leonie Felicia Becker, MD, Institute of Systems Motor Science, University of Lübeck, Germany.
A machine learning tool is able to detect facial and head tics in people with tic disorders and distinguish them from spontaneous movements in healthy controls.
Antianxiety treatment in PD improves motor function
Presenter: Nabila Dahodwala, MD, MS, University of Pennsylvania, Philadelphia, PA.
The impact of anxiety symptoms and treatment on Parkinson’s disease-related disability: Findings from the Parkinson’s Progression Markers Initiative.